Clinical Trial of Topical ABL01 Treatment of Onychomycosis

Clinical Trial of Safety and Efficacy of Topical ABL01 Treatment of Onychomycosis

This clinical trial seeks to investigate if an experimental medical device, ABL01, can be used to treat onychomycosis. In a 1-year trial the effectiveness of ABL01 will be tested against placebo in 70 study subjects with onychomycosis of the big toe nail. The endpoint of the trial is clinical improvement and cure at the 6 and 12 month time-point.

Study Overview

• Status: Completed
• Conditions: Onychomycosis of Toenail
• Intervention / Treatment: Device: ABL01; Device: Placebo

Detailed Description

The purpose of this clinical trial is to determine the safety and effectiveness of the medical device ABL01. The intended use of ABL01 is to reduce and treat onychomycosis, fungal nail infection. ABL01 is a solution intended to be topically administered weekly to infected nails. The trial is designed as a double blinded randomized placebo controlled clinical trial. The trial involves 70 study subjects, half of which will receive ABL01 and the other half placebo. The inclusion criteria for study subjects are adult men and women that present with distal lateral subungual onychomycosis (DSU) on the big toe nails. Furthermore, the extent of DSU should not involve more than half of the area of the nail.

The study subjects will themselves apply the study solution weekly to the treated nail. The trial will run for 6 months with a possible extension to maximum 12 months. There will be a total of 4 study visits at baseline, 3, 6 and 12 months to follow up the progress of the trial. The primary objective of the trial is to determine if ABL01 treatment are able to reduce and treat onychomycosis. Secondary objectives are to collect safety data, determine if the ABL01 are perceived as easy to use and assess long term effects of the treatment. The endpoint of the trial is reduction in clinical signs or complete cure of onychomycosis at the 6- or 12-month time-point.

• Study Type: Interventional
• Enrollment (Actual): 69
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden, 113 52
    • Fotcompaniet Stockholm

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Provision of written informed consent
• Men and women above age 18 weighing over 40 kg
• Present with distal lateral subungual onychomycosis of any of the big toe nails
• The onychomycosis should involve less than 50 % of the nail bed and may not have reached the cuticle

Exclusion Criteria:

• Unable to come for study visits
• Known allergy to any of the components in ABL01
• Not willing to participate in the trial or not able to understand the content of the trial
• Present with proximal subungual onychomycosis or superficial onychomycosis.
• Present with distal lateral subungual onychomycosis of other nails than the big toe.
• More than 50 % of the nailbed affected by onychomycosis or the cuticles infected
• Known conditions (like psoriasis) that cause abnormal nail appearance
• Nail damage caused by trauma, pressure or other mechanical reasons
• Currently on immunosuppressive therapy
• Showing signs of poor peripheral blood circulation
• Used another topical antifungal treatment within 1 month of screening
• Used a systemic antifungal treatment within 3 months of screening
• Participated in any other clinical onychomycosis trial in the previous 3 months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental; Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.	Device: ABL01; Experimental medical device
Placebo Comparator: Control; Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.	Device: Placebo; ABL01 lacking active component

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of study subjects with a reduction in infected nail area at 6 months.	Clinical improvement of the condition is assessed by analyzing changes in infected nail area (in relation to total nail area) due to ABL01 or placebo treatment. Clinical improvement is considered to be a 40% reduction in infected area at the 6 month time period.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Questionnaire regarding subjects opinion of the treatment, nail improvement.	Subjects score (1-5) the perceived improvement of their nail condition.	12 months
Questionnaire regarding subjects opinion of the treatment, ease of use.	Subjects score (1-5) the perceived ease of using ABL01.	12 months
Number of study subjects with treatment-related adverse events	Subject reported safety data in combination with reported adverse events and adverse device effects related to the topical administration of ABL01.	12 months
Number of study subjects with a reduction in infected area of the nail	Clinical improvement of the condition is assessed by analyzing changes in infected nail area (in relation to total nail area) due to ABL01 or placebo treatment. Clinical improvement is considered to be a 80% reduction in infected area at the 12 month time period.	12 months
Number of study subjects with clinical cure	Clinical cure is established with a negative test for dermatophytes as assessed by DNA-analysis.	12 months

Collaborators and Investigators

• Sponsor: Abbell AB
• Investigators: Principal Investigator: Irini Mouratidou-Kontorinis, Fotcompaniet Stockholm

Study record dates

Study Major Dates

• Study Start (Actual): August 14, 2017
• Primary Completion (Actual): February 8, 2019
• Study Completion (Actual): February 8, 2019

Study Registration Dates

• First Submitted: May 2, 2017
• First Submitted That Met QC Criteria: May 3, 2017
• First Posted (Actual): May 5, 2017

Study Record Updates

• Last Update Posted (Actual): February 20, 2019
• Last Update Submitted That Met QC Criteria: February 18, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Infections; Bacterial Infections and Mycoses; Skin Diseases, Infectious; Mycoses; Tinea; Dermatomycoses; Nail Diseases; Onychomycosis
• Other Study ID Numbers: AB001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No